Loading
9M
9 Meters Biopharma, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Temperato John, was filed 08 Jul 2022.
9 Meters Biopharma, Inc.: what insiders have been doing
9 Meters Biopharma, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). No insider at 9 Meters Biopharma, Inc. has published a filing in the past twelve months. The most recent one dates from 21 April 2023.
Our records for 9 Meters Biopharma, Inc. go back to 2016, with 66 purchases and 4 sales on the open market in total.
This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
126
Thresholds
n/a
Buy Volume
€2M
66 ops. · all time
Sell Volume
€18M
4 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2017FY ended December 2017 · cache
Income statement
RevenueUS$1.6M
Gross profit-US$55.1k-3% margin
Net income-US$37.7M-2324.3% margin
Last declaration on 21 April 2023
Declarations126 total
9,100 shares@ US$1.21100.0% of flowCommon stockSEC:0001551986-23-000026:0
7,885 sharesCommon StockSEC:0001578563-23-000013:0
7,885 sharesCommon StockSEC:0001578563-23-000014:0
7,885 sharesCommon StockSEC:0001578563-23-000011:0
7,885 sharesCommon StockSEC:0001578563-23-000010:0
7,885 sharesCommon StockSEC:0001578563-23-000012:0
50,177 sharesCommon StockSEC:0001578563-23-000009:0
68,815 sharesCommon StockSEC:0001578563-23-000008:0
125,000 shares@ US$0.227716.6% of flowCommon stockSEC:0001551986-22-000070:0
Canonical exit: 4 Oct 2022 (T+90)
175,000 shares@ US$0.245513.7% of flowCommon stockSEC:0001551986-22-000067:0
Canonical exit: 29 Sept 2022 (T+90)
16,000 shares@ US$0.475529.0% of flowCommon StockSEC:0001578563-22-000018:0
Canonical exit: 21 Aug 2022 (T+90)
50,000 shares@ US$0.445712.7% of flowCommon StockSEC:0001578563-22-000017:0
Canonical exit: 16 Aug 2022 (T+90)
106,383 shares@ US$0.4715.9% of flowCommon StockSEC:0001578563-22-000016:0
Canonical exit: 16 Aug 2022 (T+90)
26,508.74 shares@ US$0.754528.6% of flowCommon stockSEC:0001551986-22-000025:0
Canonical exit: 18 Nov 2020 (T+90)
86,449.55 shares@ US$0.578415.0% of flowCommon stockSEC:0001551986-22-000023:0
Canonical exit: 1 Jun 2022 (T+90)
100,000 shares@ US$0.555929.8% of flowCommon stockSEC:0001551986-22-000021:0
Canonical exit: 1 Jun 2022 (T+90)
50,000 shares@ US$0.8913.1% of flowCommon StockSEC:0001578563-21-000044:0
Canonical exit: 2 Mar 2022 (T+90)
20,000 shares@ US$1.066.2% of flowCommon stockSEC:0001551986-21-000122:0
Canonical exit: 16 Feb 2022 (T+90)
50,000 shares@ US$1.0527.6% of flowCommon stockSEC:0001551986-21-000120:0
Canonical exit: 16 Feb 2022 (T+90)
15,000 shares@ US$1.22100.0% of flowCommon stockSEC:0001551986-21-000103:0
Canonical exit: 13 Dec 2021 (T+90)
73,529 shares@ US$1.3628.2% of flowCommon stockSEC:0001551986-21-000101:0
Canonical exit: 6 Dec 2021 (T+90)
18,000 shares@ US$1.1471.0% of flowCommon stockSEC:0001551986-21-000099:0
Canonical exit: 22 Nov 2021 (T+90)
25,000 shares@ US$1.107.9% of flowCommon stockSEC:0001551986-21-000097:0
Canonical exit: 18 Nov 2021 (T+90)
25,000 shares@ US$1.0513.3% of flowCommon stockSEC:0001551986-21-000095:0
Canonical exit: 16 Nov 2021 (T+90)
319,255 shares@ US$1.382.1% of flowCommon StockSEC:0000947871-21-000712:1
25 of 126 declarations
About 9 Meters Biopharma, Inc.
9 Meters Biopharma, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ market in the United States. The company is positioned as a clinical-stage biotech focused on rare or debilitating gastrointestinal diseases, making it a niche player in digestive-disease therapeutics rather than a broad commercial pharmaceutical group. Its corporate history dates back to 2012, when it was incorporated as GI Therapeutics, Inc. It later became Innovate Biopharmaceuticals, Inc., and in April 2020 it adopted the 9 Meters Biopharma name after completing a merger with privately held RDD Pharma, Ltd. This history is important because it reflects both the company’s evolution and its strategic emphasis on gastroenterology-related science.
Operationally, 9 Meters Biopharma’s core business is the identification and development of drug candidates targeting unmet medical needs in rare digestive disorders. The company has described its pipeline around candidates such as vurolenatide, a long-acting GLP-1 agonist for short bowel syndrome, as well as earlier-stage programs in rare and/or orphan diseases. Its model is research-driven: value creation depends on advancing molecules through preclinical and clinical development, achieving regulatory milestones, and eventually securing approval or partnering opportunities. As with many development-stage biotech companies, it has historically not relied on product sales and instead has depended on capital markets, clinical data, and strategic execution.
Read moreShow less
In competitive terms, 9 Meters operates in a crowded but potentially rewarding segment of the biotech industry. Companies focused on rare gastrointestinal diseases can benefit from orphan-drug economics, specialized physician awareness, and a more targeted commercial opportunity if clinical results are positive. At the same time, the company faces the standard risks of small-cap biotech investing: scientific uncertainty, financing pressure, dilution risk, trial execution risk, and regulatory hurdles. That balance of high upside and high risk is central to the investment case.
Geographically, the company is associated with Raleigh, North Carolina, and more broadly with the United States, while its merger with RDD Pharma brought in Israeli scientific roots. For investors in France, Belgium, and Switzerland, 9 Meters Biopharma should be viewed as a speculative U.S. NASDAQ-listed biotech with a focused digestive-disease franchise and limited operating scale. Recent SEC disclosures have highlighted financing activity in 2023 and Nasdaq compliance-related issues, reinforcing the importance of monitoring liquidity, equity structure, and listing status. Insider transactions reported on Form 4 are therefore relevant signals in a company where balance-sheet management and clinical progress are critical to valuation.
